Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Immunology

Fig. 4

From: Anti-SIRT1 autoantibody is elevated in ankylosing spondylitis: a potential disease biomarker

Fig. 4

Serum levels of anti-SIRT1 antibodies in AS patients with hip joint involvement, various durations of disease and ESR levels. a. Serum anti-SIRT1 antibodies in AS patients without hip joint involvement and with involvement duration of < 1 year, 1–10 years and > 10 years from symptom onset. b. Serum anti-SIRT1 antibody levels in patients with AS duration of < 1 year, 1–10 years, 11–20 years and > 20 years from symptom onset. c. No significant differences in serum anti-SIRT1 antibody levels in ESR-positive and ESR-negative groups were found. *** P < 0.001

Back to article page